Clinical Trials Browser

Active not recruiting × INDUSTRY × apatinib × Clear all

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms